Protein deimmunization via structure-based design enables efficient epitope deletion at high mutational loads

Biotechnology and Bioengineering

Volumn 112, Issue 7, 2015, Pages 1306-1318

  Salvat, Regina S ^a   Choi, Yoonjoo ^b   Bishop, Alexandra ^c   Bailey Kellogg, Chris ^b   Griswold, Karl E ^a,d  

^a DARTMOUTH COLLEGE   (United States)

^b DARTMOUTH COLLEGE   (United States)

^c Health Services and Department of Biology   (United States)

^d Molecular and Cellular Biology Program   (United States)

Author keywords

Biotherapeutics; Computational protein design; Deimmunization; Immunogenicity; T cell epitope deletion

Indexed keywords

EPITOPES; IMMUNE SYSTEM; POLYPEPTIDES; SAFETY FACTOR; T-CELLS;

BIOTHERAPEUTICS; COMPUTATIONAL PROTEIN DESIGN; DEIMMUNIZATION; IMMUNOGENICITY; T-CELL EPITOPES;

PROTEINS;

EPITOPE; ANTIGEN; BETA LACTAMASE; BIOLOGICAL PRODUCT; PROTEIN;

ALGORITHM; ALLELE; AMINO ACID SEQUENCE; ARTICLE; COMPARATIVE STUDY; DRUG DESIGN; DRUG EFFICACY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; MAJOR HISTOCOMPATIBILITY COMPLEX; PATIENT SAFETY; PROTEIN DEIMMUNIZATION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; RISK FACTOR; SEQUENCE ALIGNMENT; T LYMPHOCYTE; THERMOSTABILITY; BIOLOGY; GENE DELETION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PROCEDURES; VALIDATION STUDY;

ANTIGENS; BETA-LACTAMASES; BIOLOGICAL PRODUCTS; COMPUTATIONAL BIOLOGY; DRUG DESIGN; EPITOPES, T-LYMPHOCYTE; HUMANS; PROTEINS; SEQUENCE DELETION;

EID: 84929953685     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.25554     Document Type: Article

References (51)

1. Aggarwal S. 2014. What's fueling the biotech engine-2012 to 2013. Nat Biotech 32(1):32-39.
2. Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. 2010. Immunogenicity of protein therapeutics: The key causes, consequences and challenges. Self Nonself 1(4):314-322.
3. Barbosa MD. 2011. Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters. Drug Discov Today 16(7-8):345-353.
4. Bateman A, Coin L, Durbin R, Finn RD, Hollich V, Griffiths-Jones S, Khanna A, Marshall M, Moxon S, Sonnhammer ELL, Studholme DJ, Yeats C, Eddy SR. 2004. The Pfam protein families database. Nucleic Acids Res 32(Suppl 1):D138-D141.
5. Bryson CJ, Jones TD, Baker MP. 2010. Prediction of immunogenicity of therapeutic proteins: Validity of computational tools. BioDrugs 24(1):1-8.
6. Cantor JR, Yoo TH, Dixit A, Iverson BL, Forsthuber TG, Georgiou G. 2011. Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift. Proc Natl Acad Sci U S A 108(4):1272-1277.
7. Chen CY, Georgiev I, Anderson AC, Donald BR. 2009. Computational structure-based redesign of enzyme activity (vol 106, pg 3764, 2009). Proc Natl Acad Sci U S A 106(18):7678-7678.
8. Choi Y, Griswold KE, Bailey-Kellogg C. 2013. Structure-based redesign of proteins for minimal T-cell epitope content. J Comput Chem 34(10):879-891.
9. Cizeau J, Grenkow DM, Brown JG, Entwistle J, MacDonald GC. 2009. Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin. J Immunother 32(6):574-584. 10.1097/CJI.0b013e3181a6981c.
10. Collen D, Bernaerts R, Declerck P, De Cock F, Demarsin E, Jenne S, Laroche Y, Lijnen HR, Silence K, Verstreken M. 1996. Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization Circulation 94(2):197-206.
11. De Groot AS, Scott DW. 2007. Immunogenicity of protein therapeutics. Trends Immunol 28(11):482-490.
12. Gainza P, Roberts KE, Donald BR. 2012. Protein design using continuous rotamers. PLoS Comput Biol 8:(1).
13. Harding FA, Liu AD, Stickler M, Razo OJ, Chin R, Faravashi N, Viola W, Graycar T, Yeung VP, Aehle W, Meijer D, Wong S, Rashid MH, Valdes AM, Schellenberger V. 2005. A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy. Mol Cancer Ther 4(11):1791-1800.
14. Harding FA, Stickler MM, Razo J, DuBridge RB. 2010. The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions. MAbs 2(3):256-265.
15. He L, Friedman AM, Bailey-Kellogg C. 2012. A divide-and-conquer approach to determine the Pareto frontier for optimization of protein engineering experiments. Proteins 80(3):790-806.
16. Hill JA, Wang D, Jevnikar AM, Cairns E, Bell DA. 2003. The relationship between predicted peptide-MHC class II affinity and T-cell activation in a HLA-DRbeta1 0401 transgenic mouse model. Arthritis Res Ther 5(1):R40-R48.
17. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C. 2006. Comparison of multiple amber force fields and development of improved protein backbone parameters. Proteins 65(3):712-725.
18. King C, Garza EN, Mazor R, Linehan JL, Pastan I, Pepper M, Baker D. 2014. Removing T-cell epitopes with computational protein design. Proc Natl Acad Sci U S A 111(23):8577-8582.
19. Lippow SM, Tidor B. 2007. Progress in computational protein design. Curr Opin Biotechnol 18(4):305-311.
20. Lovell SC, Word JM, Richardson JS, Richardson DC. 2000. The penultimate rotamer library. Proteins 40(3):389-408.
21. Mazor R, Eberle JA, Hu X, Vassall AN, Onda M, Beers R, Lee EC, Kreitman RJ, Lee B, Baker D, King C, Hassan R, Benhar I, Pastan I. 2014. Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes. Proc Natl Acad Sci U S A 111(23):8571-8576.
22. Mazor R, Vassall AN, Eberle JA, Beers R, Weldon JE, Venzon DJ, Tsang KY, Benhar I, Pastan I. 2012. Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A. Proc Natl Acad Sci 109(51):E3597-E3603.
23. Mccaldon P, Argos P. 1988. Oligopeptide biases in protein sequences and their use in predicting protein coding regions in nucleotide-sequences. Proteins 4(2):99-122.
24. Moise L, McMurry J, Rivera DS, Carter EJ, Lee J, Kornfeld H, Martin WD, De Groot AS. 2007. Progress towards a genome-derived, epitope-driven vaccine for latent TB infection. Med Health R I 90(10):301-303.
25. Moise L, Song C, Martin WD, Tassone R, De Groot AS, Scott DW. 2012. Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo. Clin Immunol 142(3):320-331.
26. Muraro PA, Vergelli M, Kalbus M, Banks DE, Nagle JW, Tranquill LR, Nepom GT, Biddison WE, McFarland HF, Martin R. 1997. Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residues 111-129) in HLA-DR4 (B1 0401) subjects is associated with a restricted T cell receptor repertoire. J Clin Investig 100(2):339-349.
27. Niesen FH, Berglund H, Vedadi M. 2007. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protocols 2(9):2212-2221.
28. Nielsen M, Lund O, Buus S, Lundegaard C. 2010. MHC Class II epitope predictive algorithms. Immunology 130(3):319-328.
29. Nielsen M, Lundegaard C, Lund O. 2007. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinform 8:238.
30. Osipovitch DC, Parker AS, Makokha CD, Desrosiers J, Kett WC, Moise L, Bailey-Kellogg C, Griswold KE. 2012. Design and analysis of immune-evading enzymes for ADEPT therapy. Protein Eng Des Sel 25(10):613-623.
31. Parker AS, Choi Y, Griswold KE, Bailey-Kellogg C. 2013. Structure-guided deimmunization of therapeutic proteins. J Comput Biol 20(2):152-165.
32. Parker AS, Griswold KE, Bailey-Kellogg C. 2011. Optimization of therapeutic proteins to delete T-cell epitopes while maintaining beneficial residue interactions. J Bioinform Comput Biol 9(2):207-229.
33. Parker AS, Zheng W, Griswold KE, Bailey-Kellogg C. 2010. Optimization algorithms for functional deimmunization of therapeutic proteins. BMC Bioinform 11:180.
34. Paul S, Kolla RV, Sidney J, Weiskopf D, Fleri W, Kim Y, Peters B, Sette A. 2013. Evaluating the immunogenicity of protein drugs by applying in vitro MHC binding data and the immune epitope database and analysis resource. Clin Dev Immunol 2013:467852.
35. Pearlman DA, Case DA, Caldwell JW, Ross WS, Cheatham TE, Debolt S, Ferguson D, Seibel G, Kollman P. 1995. Amber, a package of computer-programs for applying molecular mechanics, normal-mode analysis, molecular-dynamics and free-energy calculations to simulate the structural and energetic properties of molecules. Comput Phys Commun 91(1-3):1-141.
36. Ponder J. 2011. TINKER: Software tools for molecular design (version 6.0).
37. Salvat RS, Moise LCB-K, Griswold KE. 2014a. A high throughput MHC II binding assay for quantitative analysis of peptide epitopes. J Vis Exp 85:e51308.
38. Salvat RS, Parker AS, Choi Y, Bailey-Kellogg C, Griswold KE. 2015. Mapping the pareto optimal design space for a functionally deimmunized biotherapeutic candidate. PLoS Comput Biol 11(1):e1003988.
39. Salvat R, Parker A, Guilliams A, Choi Y, Bailey-Kellogg C, Griswold K. 2014b. Computationally driven deletion of broadly distributed T cell epitopes in a biotherapeutic candidate. Cell Mol Life Sci 71(24):4869-4880.
40. Schellekens H. 2002. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 1(6):457-462.
41. Schellekens H. 2010. The immunogenicity of therapeutic proteins. Discovery Med 49:560-564.
42. Sidney J, del Guercio MF, Southwood S, Sette A. 2002. The HLA molecules DQA1 0501/B1 0201 and DQA1 0301/B1 0302 share an extensive overlap in peptide binding specificity. J Immunol 169(9):5098-5108.
43. Singh H, Raghava GP. 2001. ProPred: Prediction of HLA-DR binding sites. Bioinformatics 17(12):1236-1237.
44. Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, Hoffman S, Kubo RT, Chesnut RW, Grey HM, Sette A. 1998. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 160(7):3363-3373.
45. Steere AC, Klitz W, Drouin EE, Falk BA, Kwok WW, Nepom GT, Baxter-Lowe LA. 2006. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med 203(4):961-971.
46. Still WC, Tempczyk A, Hawley RC, Hendrickson T. 1990. Semianalytical treatment of solvation for molecular mechanics and dynamics. J Am Chem Soc 112(16):6127-6129.
47. Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, Sahin U, Braxenthaler M, Gallazzi F, Protti MP, Sinigaglia F, Hammer J. 1999. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotech 17(6):555-561.
48. Trombetta ES, Mellman I. 2005. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 23(1):975-1028.
49. Wang P, Sidney J, Dow C, Mothe B, Sette A, Peters B. 2008. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol 4(4):e1000048.
50. Weaver JM, Sant AJ. 2009. Understanding the focused CD4 T cell response to antigen and pathogenic organisms. Immunologic Res 45(2-3):123-143.
51. Yeung VP, Chang J, Miller J, Barnett C, Stickler M, Harding FA. 2004. Elimination of an immunodominant CD4+ T cell epitope in human IFN-β does not result in an in vivo response directed at the subdominant epitope. J Immunol 172(11):6658-6665.